A detailed history of First Horizon Advisors, Inc. transactions in Argenx Se stock. As of the latest transaction made, First Horizon Advisors, Inc. holds 139 shares of ARGX stock, worth $84,222. This represents 0.0% of its overall portfolio holdings.

Number of Shares
139
Previous 117 18.8%
Holding current value
$84,222
Previous $50,000 50.0%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$434.22 - $551.9 $9,552 - $12,141
22 Added 18.8%
139 $75,000
Q1 2024

Apr 26, 2024

SELL
$356.95 - $413.29 $713 - $826
-2 Reduced 1.68%
117 $46,000
Q3 2023

Oct 27, 2023

BUY
$369.35 - $548.43 $369 - $548
1 Added 0.85%
119 $58,000
Q2 2023

Aug 03, 2023

BUY
$360.14 - $422.58 $360 - $422
1 Added 0.85%
118 $45,000
Q1 2023

May 15, 2023

SELL
$334.23 - $403.65 $1,002 - $1,210
-3 Reduced 2.5%
117 $43,000
Q4 2022

Feb 10, 2023

SELL
$342.17 - $402.31 $1,368 - $1,609
-4 Reduced 3.23%
120 $45,000
Q3 2022

Nov 09, 2022

SELL
$343.2 - $395.75 $686 - $791
-2 Reduced 1.59%
124 $43,000
Q2 2022

Aug 02, 2022

BUY
$269.58 - $378.88 $33,967 - $47,738
126 New
126 $47,000
Q1 2022

May 10, 2022

SELL
$254.45 - $351.06 $23,154 - $31,946
-91 Closed
0 $0
Q4 2021

Feb 09, 2022

BUY
$272.01 - $353.03 $1,904 - $2,471
7 Added 8.33%
91 $31,000
Q3 2021

Nov 15, 2021

BUY
$295.0 - $350.58 $295 - $350
1 Added 1.2%
84 $25,000
Q3 2021

Nov 09, 2021

BUY
$295.0 - $350.58 $885 - $1,051
3 Added 3.75%
83 $25,000
Q1 2021

May 11, 2021

SELL
$268.3 - $380.31 $536 - $760
-2 Reduced 2.44%
80 $22,000
Q3 2020

Nov 12, 2020

SELL
$215.51 - $272.51 $6,249 - $7,902
-29 Reduced 26.13%
82 $21,000
Q2 2020

Jul 31, 2020

BUY
$127.44 - $232.72 $3,695 - $6,748
29 Added 35.37%
111 $25,000
Q4 2019

Jan 07, 2020

BUY
$106.59 - $164.21 $8,740 - $13,465
82 New
82 $13,000

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $33.5B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track First Horizon Advisors, Inc. Portfolio

Follow First Horizon Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Horizon Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on First Horizon Advisors, Inc. with notifications on news.